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Abstract
Screeninga libraryof drugswithknown safetyprofiles inhumans yielded 30drugs thatreliably protectedmammalianneurons
against glucose toxicity. Subsequent screening demonstrated that 6 of these 30 drugs increase lifespan in C. elegans: caffeine,
ciclopirox olamine, tannic acid, acetaminophen, bacitracin, and baicalein. Every drug significantly reduced the age-dependent
acceleration of mortality rate. These protective effects were blocked by RNAi inhibition of cbp-1 in adults only, which also
blocks protective effects of dietary restriction. Only 2 drugs, caffeine and tannic acid, exhibited a similar dependency on DAF-
16. Caffeine, tannic acid, and bacitracin also reduced pathology in a transgenic model of proteotoxicity associated with
Alzheimer’s disease.These results further supporta key role for glucose toxicity indriving age-related pathologies andfor CBP-
1inprotectionagainstage-relatedpathologies.Theseresultsalsoprovidenovelleadcompounds withknown safetyprofilesin
human for treatment of age-related diseases, including Alzheimer’s disease and diabetic complications.
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Introduction
A promising implication of aging research is that interventions
directed at fundamental processes of aging may mimic the broad
protective effects of dietary restriction against age-related pathol-
ogies (e.g., activation of sirtuins by resveratrol [1]). Furthermore,
the discovery that specific drugs increase lifespan has led to new
insight of the role the targets of these drugs play in the aging
process. For example, screening drugs from a variety of functional
classes and structure led to the discovery that anti-convulsant
drugs extend lifespan in C. elegans, supporting an unexpected role
of neuronal activity in determining lifespan [2]. Similarly, a screen
of over 88,000 compounds led to the discovery that the anti-
depressant drug mianserin extends lifespan in C. elegans, supporting
a novel role for serotonin in determining lifespan [3]. Other
studies in C. elegans on the role of the TOR pathway in determining
lifespan [4] led to the discovery that rapamycin extends lifespan in
mice [5], crucially supporting that the mTOR pathway plays a key
role in mammalian aging and providing a lead compound for a
variety of age-related diseases, especially cancer.
We have recently reported that the protective effects of dietary
restriction and ablation of the insulin-like pathway require
induction of the transcriptional co-activator Creb-binding protein
(Cbp), whose expression in the hypothalamus of mice also
accounts for over 80% of lifespan variance in 5 strains of mice
[6]. This study also suggested that the protective effects of dietary
restriction and Cbp are mediated by a metabolic shift away from
glucose utilization and toward beta oxidation [6]. These and other
observations [7,8] suggest that drugs which protect against glucose
toxicity would plausibly mimic many of the protective effects of
dietary restriction, including a reduction in age-dependent
acceleration of mortality rate [9]. We also hypothesized that the
protective effects of such drugs would depend on CBP-1 and
possibly DAF-16 [6].
To address this hypothesis we developed a high-throughput
screen to discover drugs that protect against glucose toxicity in
mammalian neurons, since, as indicated above, growing evidence
indicates that neurons play a key role in aging and the protective
effects of dietary restriction [10]. We focused on a library of drugs
with established safety profiles in humans, mainly drugs approved
for use in humans by the FDA, since such drugs would be most
readily translated for clinical use [11]. Drugs corroborated to be
protective in mammalian neurons were then screened for activity
to increase lifespan, reduce age-related acceleration of mortality
rate, and reduce pathology in a transgenic model for proteotoxi-
city in Alzheimer’s disease (CL2006) [12]. Finally, we assessed if
protective effects of these drugs depend on DAF-16 or CBP-1.
Results
Thirty drugs that protect against glucose toxicity in
mammalian neurons
Many lines of evidence suggest that glucose metabolism and
toxicity contribute to both aging [8] and diabetic complications
PLoS ONE | www.plosone.org 1 November 2011 | Volume 6 | Issue 11 | e27762[13]. We therefore hypothesized that drugs which ameliorate
glucose-induced vulnerability to oxidative stress would also protect
against toxicity during aging. To discover such drugs we developed
an assay to assess glucose-induced toxicity in neurons [14]. The
primary screen, utilizing dye-based assay for neuronal viability,
yielded 42 drugs that significantly enhanced viability at 15 mM
glucose (p,0.05, .50% enhanced viability). These 42 protective
drugs were then screened using a secondary assay, measuring
lactate dehydrogenase released into the medium as a marker of cell
death. Thirty of these 42 drugs significantly reduced neuronal
death at 15 mM glucose (Table 1). Dose-response curves were
then generated for each drug, which corroborated that all drugs
enhanced neuronal viability at 15 mM glucose in the presence of
oxidative stress (Table 1 and Figure S1).
Caffeine increases lifespan and slows aging dependent
on DAF-16 and CBP-1 and delays proteotoxicity
To assess if these drugs would be protective during aging, effects
of each drug on lifespan were assessed in adult N2 C. elegans,a t
concentrations of 0.01, 0.1, and 1%. Seven of the thirty drugs
produced significant increases in lifespan for at least one
concentration (often the drugs increased lifespan at one concen-
tration and reduced lifespan at a higher concentration). After the
initial screen indicated that at least one concentration of these
drugs increased lifespan, the protective effects of each drug at the
optimum dose was corroborated using at least two more detailed
analyses of survival curves in wild-type worms as well as in the
Abeta transgenic model of Alzheimer’s disease proteotoxicity. For
example, caffeine at 0.1% increased maximum lifespan by 52%
Table 1. Drugs that protect against glucose induced hydrogen peroxide toxicity in mouse primary neurocytes.
Drug %LDH (Mean) %LDH (Sem) EC 50 Human dosage LD 50
CAFFEINE 26.0 6.5 14.1 100–200 mg/4 hrs 192 mg/kg oral
CICLOPIROX OLAMINE 17.5 4.7 1.1 NA NA
TANNIC ACID 27.1 6.2 0.17 NA 1000 mg/kg oral
ACETAMINOPHEN 47.4 8.7 8.2 90 mg/kg/day 1944 mg/kg oral
BACITRACIN 27.1 7.6 34.6 NA .3750 mg/kg oral
BAICALEIN 47.8 16.1 18.6 NA NA
HYDRALAZINE HCl 33.5 14.3 92.3 7.5 mg/kg max 173–187 mg/kg oral
POTASSIUM p-AMINOBENZOATE 15.4 6.5 5.2 NA NA
AMILORIDE HCl 23.4 2.4 18.2 5–10 mg/day 36–85 mg/kg oral
METHACYCLINE HCl 23.8 5.2 53.8 8.5 mg/kg/day 252 mg/kg IP
2-THIOURACIL 27.3 11.2 23.6 30–60 mg/day 2100 mg/kg oral
AMINOGLUTETHIMIDE 31.0 13.2 32.3 250mg/6 hrs 625 mg/kg IP*
PROTHIONAMIDE 32.0 12.1 5.8 1000 mg/day 1320 mg/kg oral
AESCULIN 32.3 7.6 44.8 100–150 mg/day NA
PINDOLOL 33.6 5.4 5.1 10–60 mg/day 263 mg/kg oral
TOLAZAMIDE 33.6 5.4 13.1 100–1000 mg/day 200 mg/kg oral*
BERBAMINE HCl 35.4 8.9 88.8 150 mg/6 hrs 15000 mg/kg oral
FENBUFEN 35.7 5.3 42.6 4.285 mg/kg/8 hrs 800 mg/kg oral
BETAMETHASONE 38.5 11.5 62.5 .6–7.2 mg/day 1607 mg/kg oral*
BACLOFEN 39.0 0.6 95.7 40–80 mg/day 145 mg/kg oral
3,5-DINITROCATECHOL 39.8 8.0 60.6 NA 500 mg/kg oral*
PIPERINE 42.3 8.3 69.5 10 mg/day 514 mg/kg oral
CHLORZOXAZONE 43.1 3.7 85.5 250–750 mg/6 hrs 763 mg/kg oral
BUSULFAN 43.2 12.6 10.3 2–4 mg/kg/day 15 mg/kg oral
BITHIONOL 43.7 10.6 88.0 5–25 mg/day 7 mg/kg oral
AMPROLIUM 44.6 5.6 14.4 NA 6170 mg/kg oral*
DIHYDROJASMONIC ACID 45.3 2.6 95.2 NA NA
TRANYLCYPROMINE SULFATE 46.3 10.2 102.5 30–60 mg/day 30 mg/kg IP
ANTIPYRINE 49.3 21.5 86.8 NA 1750 mg/kg oral
SODIUM p-AMINOSALICYLATE 56.5 5.7 10.0 5–6 g/12 hrs 8000 mg/kg oral
ETODOLAC 77.7 2.7 88.3 1000 mg/day 94 mg/kg oral
The first seven drugs represent candidates that also have positive effects in C. elegans models. The remaining dugs are ranked according to their effectiveness in
comparison to untreated controls (%LDH (mean)). The effective concentration in culture is represented as ‘‘EC 50.’’ When available, normal human dosages and lethal
mammalian dose (LD 50) in rat, unless stated otherwise, are listed. Chemical formula, molecular weight, and current uses for the drugs (Function) are shown.
*LD 50 performed in mouse.
doi:10.1371/journal.pone.0027762.t001
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lifespan (p,0.01 by log rank Mantel-Cox test; n=45) (Figure 1A).
Protective effects of caffeine were completely blocked by inhibition
of either DAF-16 (Figure 1B) or CBP-1 (Figure 1C) by RNAi.
Finally, 0.1% caffeine also significantly delayed pathology in a
transgenic Abeta C. elegans model of proteotoxicity in Alzheimer’s
disease (p,0.01; n=30). Caffeine also reduced age-dependent
acceleration of mortality rate by 53%, and this protective effect
was also blocked by RNAi inhibition of CBP-1 or DAF-16
(Table 2).
Ciclopirox increases lifespan and slows aging, but does
not delay proteotoxicity
Ciclopirox olamine (0.01%), used to treat dermatological fungus
infections, also increased maximum lifespan by 52% (Table 3) and
significantly increased median lifespan (p,0.01 by Mantel-Cox
log rank test; n=45) (Figure 2A). In contrast to caffeine, ciclopirox
increased lifespan even when daf-16 was inhibited by RNAi
(Figure 2B) (p,0.01; n=30). Like the other drugs tested, cbp-1
inhibition by RNAi blocked the effect of ciclopirox to increase
maximum lifespan. However, unlike the other drugs in this study,
the effect on median lifespan produced by ciclopirox, while
reduced, was still significant (p,0.01; n=30). Furthermore, like
caffeine, ciclopirox reduced age-dependent acceleration of mor-
tality rate (Table 2). Interestingly, inhibition of both daf-16 and
cbp-1 not only blocked this protective effect but even appeared to
unmask a toxic effect of ciclopirox to enhance age-related
acceleration of mortality rate accompanied by a striking reduction
in initial mortality rate (Table 2). A similar effect was observed for
caffeine, though this did not achieve statistical significance
(Table 2). In further contrast with caffeine, ciclopirox did not
protect against pathology associated with proteotoxicity
(Figure 2D), and in fact at the 1% concentration accelerated that
pathology (not shown).
Tannic acid increases lifespan and slows aging
dependent on DAF-16 and CBP-1 and delays
proteotoxicity
Tannic acid (0.01%), a highly soluble polyphenol, increased
maximum lifespan by 59% (Table 3) and significantly increased
median lifespan (P,0.01 by Mantel-Cox log rank test; n=45)
(Figure 3A). As with caffeine, inhibition of DAF-16 (Figure 3B) or
CBP-1 (Figure 3C) blocked the effect of tannic acid to increase
lifespan. As with caffeine and ciplopirox, tannic acid also reduced
age-related acceleration of mortality rate, and inhibition of either
and CBP-1 or DAF-16 prevented this protective effect (Table 2).
Tannic acid also produced a striking delay in the onset of
pathology associated with proteotoxicity, such that at day 13, only
15% of control worms remained mobile compared to 45% of
worms treated with tannic acid (P,0.01; n=30) (Figure 3D).
However, tannic acid at 1% concentration significantly reduced
lifespan.
Figure 1. Caffeine increased maximum and median lifespan
dependent on DAF-16 and CBP-1 and delays toxicity in a
transgenic model of Alzheimer’s disease. A. Caffeine (0.1%)
increases maximum and median lifespan (P,0.01). B. Caffeine does
not increase lifespan when daf-16 is inhibited by RNAi. C. Caffeine does
not increase lifespan when cbp-1 is inhibited by RNAi. D. Paralysis is
delayed and survival of the Abeta Tg is increased with 0.1% caffeine vs.
vehicle (P,01).
doi:10.1371/journal.pone.0027762.g001
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and does not delay proteotoxicty
Acetaminophen (0.01%), a non-steroidal anti-inflammatory
drug, increased maximum lifespan by 66% (Table 3) and
significantly increased median lifespan (P,0.01; N=45)
(Figure 4A). Inhibition of DAF-16 did not prevent the effect of
acetaminophen to increase lifespan (Figure 4B), but inhibition of
CBP-1 completely prevented the protective effects of acetamino-
phen (Figure 4C). Acetaminophen differed from the drugs
described above in that the extension of lifespan was not associated
with reduction in acceleration of mortality rate under standard
condition (Table 2). However, when daf-16 was inhibited
acetaminophen significantly reduced acceleration of mortality rate
(Table 2), further supporting that the protective effect of this drug
is independent of DAF-16. In contrast, when cbp-1 was inhibited,
acetaminophen if anything increased mortality rate, again
supporting that the protective effects of acetaminophen depends
on CBP-1. However, acetaminophen failed to delay the onset of
pathology associated with proteotoxicity. At a higher concentra-
tion (1%) acetaminophen significantly reduced lifespan (not
shown).
Bacitracin increases lifespan dependent of CBP-1 and
delays proteotoxcity
Bacitracin (1%), a topical antibiotic, increased maximum
lifespan by 74% (Table 3) and significantly increased median
lifespan (Figure 5A) (P,0.01; n=45). Inhibition of DAF-16
reduced the life-extending effect of bacitracin but did not
completely block it (Figure 5B; p,0.01; n=35). In contrast,
inhibition of cbp-1 completely blocked the life-extending effect of
bacitracin (Figure 5C). Like acetaminophen, bacitracin increased
lifespan without significantly reducing age-associated acceleration
of mortality rate (Table 2). However, bacitracin did reduce
acceleration of mortality rate when daf-16 is inhibited (which
increased mortality rate), an effect not observed with cbp-1 was
inhibited (Table 2). These results further demonstrate that the
protective effects of bacitracin are independent of DAF-16 but
dependent on CBP-1. Bacitracin also significantly delayed
pathology associated with proteotoxicity (P.0.02; n=30).
Baicalein increases lifespan and slows aging dependent
on CBP-1 but does not significantly delay proteotoxicity
Baicalein (0.1%), an anti-inflammatory component of a
traditional Chinese herbal preparation [15], increased maximum
lifespan by 52% and significantly increased median lifespan
(Figure 6A; p,0.01; n=45). Although inhibition of DAF-16
substantially reduced the protective effects of baicalein, the drug
still significantly increased lifespan when daf-16 was inhibited by
RNAi (Figure 6B; p=0.01; n=28). In contrast cbp-1 RNAi
Table 2. Average G-value gathered by maximum likely-hood
estimates methods.
a(x10
5) g(X10
2)
N2 Vehicle (n=45) 25.58 30.55
N2 Caffeine (n=45) 102.73 16.73*
daf-16(RNAi) Vehicle (n=32) 34.96 40.83
daf-16(RNAi) Caffeine (n=20) 1.71 56.89
cbp-1 (RNAi) Vehicle (n=40) 7.63 49.36
cbp-1 (RNAi) Caffeine (n=32) 8.75 53.32
N2 Vehicle (n=45) 25.58 30.55
N2 CPX(n=45) 24.59 20.27*
daf-16(RNAi) Vehicle (n=32) 34.96 40.83
daf-16(RNAi) CPX (n=30) 0.06 65.37*
cbp-1 (RNAi) Vehicle (n=40) 7.64 49.36
cbp-1 (RNAi) CPX (n=30) 0.26 65.48
N2 Vehicle (n=45) 25.58 30.55
N2 Tannic Acid (n=45) 152.53 16.26*
daf-16(RNAi) Vehicle (n=28) 28.42 51.02
daf-16(RNAi) Tannic Acid (n=15) 80.2 37.41
cbp-1 (RNAi) Vehicle (n=26) 32.74 58.39
cbp-1 (RNAi) Tannic Acid (n=24) 14.11 71.84
N2 Vehicle (n=45) 115.72 18.66
N2 Acetaminophen (n=45) 43.07 19.45
daf-16(RNAi) Vehicle (n=32) 34.96 40.83
daf-16(RNAi) Acetaminophen (n=30) 270.76 19.38*
cbp-1 (RNAi) Vehicle (n=40) 7.64 49.36
cbp-1 (RNAi) Acetaminophen (n=45) 0.6 63.51
N2 Vehicle (n=45) 115.72 18.66
N2 Bacitracin (n=45) 104.29 16.09
daf-16(RNAi) Vehicle (n=32) 34.96 40.83
daf-16(RNAi) Bacitracin (n=35) 265.53 20.20*
cbp-1 (RNAi) Vehicle (n=40) 7.64 49.36
cbp-1 (RNAi) Bacitracin (n=46) 4.22 56.53
N2 Vehicle (n=45) 25.58 30.55
N2 Bacailene (n=45) 68.57 17.34*
daf-16(RNAi) Vehicle (n=29) 1.3 62.68
daf-16(RNAi) Bacailene (n=28) 44.9 35.08*
cbp-1 (RNAi) Vehicle (n=29) 2.98 58.53
cbp-1 (RNAi) Bacailene (n=30) 2.82 65.1
*Significant decrease in values (as measured by one-sided chi squared).
The relative rate of aging as measured by Gompertz’s analysis. The change in
the initial or age- independent rate of mortality relative to vehicle treated
controls (a). The change in age-dependent mortality rate, or Gompertz’s
variable (g) in relation to vehicle treated controls.
doi:10.1371/journal.pone.0027762.t002
Table 3. N2 Lifespan.
Drug Mean Sem +/2 Min Max Number (n)
Vehicle 21.31 0.58 11 27 45
Caffeine 27.58 0.51 17 41 45
CPX 29.98 0.43 11 39 45
Tannic acid 26.60 0.50 17 43 45
Acetaminophen 31.67 0.43 23 47 45
Bacitracin 33.78 0.37 17 47 45
Baicalein 29.13 0.44 17 41 45
Lifespan of C. elegans (N2) in the presence of drugs administered at the optimal
concentration. The average mean lifespan (in days) and the standard deviation
were calculated from experiments (45 total worms per condition). Min and Max
mark the first and last day (respectively) that an animal was scored as dead.
doi:10.1371/journal.pone.0027762.t003
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(Figure 6C). Interestingly, even though baicalein protects against
Abeta toxicity in mammalian neurons [16], at the concentration
that extended lifespan the compound did not significantly reduce
pathology associated with Abeta proteotoxicity in C. elegans
(Figure 6D).
Discussion
In the present studies 1.5% of the drugs screened protected
against glucose toxicity and a striking 23% of these drugs
significantly increased lifespan. By comparison, in an unbiased
screen of 88,000 compounds, only 0.13% of the drugs increased
lifespan (half of which increased lifespan by less than 10%). Of the
drugs that increased lifespan, 86% slowed the rate of aging, as
indicated by analysis of mortality rate statistics [17] using a
recently validated algorithm [18]. Inhibition of cbp-1blocked the
protective effects of these drugs during aging just as it inhibits
protective effects of dietary restriction (but not cold) [6]. In
contrast only a few of the protective effects of these were
dependent on DAF-16, just as the protective effects of only some
methods of dietary restriction are dependent on DAF-16 [6,19].
These observations are consistent with other evidence that glucose
metabolism and toxicity play a prominent role in driving the aging
process [7,8,20], as it does diabetic complications [13]. Similarly
these studies support that a reduction in glucose toxicity mediates
protective effects of dietary restriction during aging dependent on
the activity of Cbp [6].
The present studies began with a blinded screen of the
Spectrum Collection (Microsource) for potential protective effects
against glucose toxicity in mammalian neuron and thus for
potential use to prevent or reverse complications of diabetes.
Similar screens of this library of compounds, most of which have
known safety profiles for use in humans, have led to the potential
repositioning of therapeutic drugs with known safety profiles for
novel therapeutic purposes [11]. A major consideration when
carrying out such screens is the challenge of obtaining the
optimally protective dose, since protective compounds are
generally toxic at higher doses. Indeed we observed in the initial
screen in mammalian neurons that at the screening concentration
many drugs were in fact toxic. Therefore we screened three
concentrations in C. elegans and found that many of the drugs at the
highest concentration examined (1%) reduced lifespan, whereas at
lower concentrations some drugs increased lifespan. A related
concern is the extent to which the protective concentrations
observed in the C. elegans study, in which the compounds were
added to the environment, would translate to doses that are safe to
use in humans or other mammals. In the present study we
screened at concentrations from 0.01 to 1% (roughly 100 uM to
10 mM) in the medium because such concentrations often
produce similar effects in C. elegans as is produced at therapeutic
doses in humans (e.g., fluoxetine [21]), although of course it is not
clear precisely what is the tissue concentration of the drug in the
worm under these conditions.
Figure 2. Ciclopirox olamine increases N2 longevity in a CBP-1
and DAF-16 independent, manner but fails to rescue A-beta
toxicity. A. N2 longevity is increased with .01% ciclopirox olamine vs.
vehicle (P,0.01). B. Survival of daf-16 (RNAi) is increased with .01%
ciclopirox olamine vs. vehicle (P,0.01). C. Survival of cbp-1 (RNAi) is
increased with .01% ciclopirox olamine vs. untreated control (P,.01). D.
Survival of Abeta Tg is unchanged with .01% ciclopirox olamine vs.
vehicle.
doi:10.1371/journal.pone.0027762.g002
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many cases mechanisms of protective action have been studied,
they make promising lead compounds to treat age-related diseases
including diabetes and Alzheimer’s disease. Thus caffeine
(ED50=12 mg/kg; LD50=200 mg/kg) was effective at a 0.1%
concentration (5.1 mM) to increase lifespan and reduce proteo-
toxicity, corroborating a similar result that 3.6 mM caffeine added
to the medium reduced pathology in the same transgenic model of
proteotoxicity associated with Alzheimer’s disease [22]. Many
epidemiological studies have observed that consumption of coffee
and other caffeinated drinks appears to be highly protective
against a variety of pathologies including Parkinson’s disease [23]
and Alzheimer’s disease [24]. Similarly, administration of caffeine
in experimental models of these diseases is protective [25]. Many
mechanisms have been suggested to mediate these protective
effects of caffeine, but none have yet been established [24].
Ciclopirox is used clinically as a topical antifungal agent so an
ED50 for oral doses is not known. However, the LD50 for oral
doses is about 2000 mg/kg (e.g., 10-fold higher than for caffeine)
and it was protective at a concentration 10-fold lower than for
caffeine. Interestingly ciclopirox protects PC12 neuronal cells from
cell death after removal of trophic support [26], and protects
astrocytes from peroxynitrate toxicity by maintaining mitochon-
drial function, through unknown mechanisms. Tannic acid also
exhibits an LD50 of about 2000 mg/kg and protects neurons [27]
and produces many other protective effects; although many
mechanisms have been suggested, none have been established
[28]. Interestingly acetaminophen (LD50 about 1000 mg/kg)
protects both neurons and brain endothelial cells against oxidative
stress through a mechanism that may entail inhibition of apoptosis
[29,30]. Bacitracin (LD50 about 1000 mg/kg) is a topical
antibiotic but also appears to specifically inhibit cholinesterases
associated with plaques and tangles in Alzheimer’s disease [31].
Although an antibiotic, the mechanism by which bacitracin
increases lifespan is probably not mediated by dietary restriction
secondary to reduced bacterial growth, since dietary restriction
reduces the rate of aging in C. elegans [9] whereas bacitracin did not
reduce the rate of aging (Table 2). Baicalein is an anti-
inflammatory flavanoid isolated from the traditional Chinese
herbal preparation known as hua ´ng qı ´n (derived from Scutellaria
baicalensis) which has been shown to protect neurons against beta-
amyloid toxicity [16] and other insults including ischemic stroke
[32] through unknown mechanisms.
Thus all the compounds discovered in this screen have been
shown to be neuroprotective under various circumstances but the
only clear common denominator is that the mechanisms by which
these diverse compounds exert their protective effects remain
unclear. It is therefore of particular interest that the protective
effects of each of these compounds is blocked by inhibition of cbp-1
by RNAi whereas similar inhibition of daf-16 only blocked
protective effects of 2 of these compounds. Since RNAi does not
completely block expression of DAF-16 in all cells this does not
rule out that DAF-16 plays a role in mediating some of these
protective effects. Nevertheless the evidence clearly supports a
Figure 3. Tannic acid increases N2 longevity in a CBP-1 and
DAF-16 dependent, manner and reduces Abeta toxicity. A. N2
longevity is increased with .01% tannic acid vs. vehicle (P,0.01). B.
Survival of daf-16 (RNAi) is unchanged with .01% tannic acid vs. vehicle.
C. Survival of cbp-1 (RNAi) is unchanged with .01% tannic acid vs.
untreated control. D. Survival of A-beta Tg is increased with .01% tannic
acid vs. vehicle (P=0.01).
doi:10.1371/journal.pone.0027762.g003
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protective effects of these drugs as it does in several protocols of
dietary restriction [6]. Since the protective effects of these drugs
was based on a screen for neuroprotection against glucose toxicity,
against which CBP-1 also appears to be particularly protective [6],
it is probably not a coincidence that the protective effects of these
drugs are also largely dependent on CBP-1. On the other hand
while 5 of the 6 drugs reduce the rate of aging and thus mimic the
effects of dietary restriction (caffeine, ciclopirox, tannic acid,
baicalein and, when daf-16 is inhibited, bacitracin and acetamin-
ophen). Similarly while 3 of the 6 drugs delayed pathology in a
model of proteotoxicity associated with Alzheimer’s disease
(caffeine, bacitracin, and tannic acid), 3 did not. Thus, while the
protective effects of all these drugs appear to depend on CBP-1,
there are apparently other differences in mechanisms mediating
the protective effects of these drugs.
In conclusion the present studies demonstrate that drugs which
protect against glucose toxicity exhibit a remarkably high
probability of increasing lifespan and reducing proteotoxicity.
Furthermore these protective effects, like protective effects of
dietary restriction and DAF-16, are highly dependent on the
transcriptional factor CBP-1, but much less so, on DAF-16.
Finally, the present studies greatly extend the number of
corroborated drugs that may protect against a wide range of
age-related pathologies including diabetic complications, Alzhei-
mer’s disease, and the rate of aging itself.
Methods
C. elegans strains
All strains were obtained from the Caenorhabditis Genetics
Center, funded by the NIH National Center for Research
Resources (NCRR), and maintained at 20u C, under standard
conditions [33]. Strain CL2006, dvIs2[pCL12(unc-54/human Abeta
peptide 1-42 minigene) + pRF4], used as a model for proteotoxicity in
Alzheimer’s disease, was created by Chris Link [12].
Drug screen
The initial drug screen was from a compound library based on
the Spectrum Collection (Microsource), as prepared and coded by
the Juvenile Diabetes Research Foundation. The screen entailed
assessing viability of primary (E16) cortical neurons after a 1-hour
exposure to a low dose (30 uM) of hydrogen peroxide, using two
distinct 96-well-based assays for neuronal viability. In contrast to
some in vitro models of hyperglycemia, which show direct toxic
effects of extremely high, non-physiological (often above 30 mM)
levels of glucose, 15 mM glucose did not directly reduce neuronal
viability, compared to 5 mM glucose. However, after a brief
exposure to 100 uM hydrogen peroxide (determined by a dose-
response curve), incubation at 15 mM glucose reduced neuronal
viability 24 hours later by 75%, compared to 5 mM glucose.
Twenty-four hours later, medium was removed and stored for
subsequent assay of lactate dehydrogenase (Promega), or a viability
assay (CKK-8; Dojindo Molecular Technologies). The wells were
incubated and read by an ELISA reader at 450 nm, according to
the manufacturer’s instructions. Any drug producing a statistically
significant increase in cell viability by the CCK-8 assay (n=8
cells/drug at 15 mM glucose/100 uM hydrogen peroxide) was re-
Figure 4. Acetaminophen increases N2 longevity in a CBP-1
dependent, but DAF-16 independent, manner but fails to
rescue Abeta toxicity. A. N2 longevity is increased with 0.1%
acetaminophen vs. vehicle (P,0.01). B. Survival of daf-16 (RNAi) is
increased with 0.1% acetaminophen vs. vehicle (P,0.01). C. Survival of
cbp-1 (RNAi) is unchanged with 0.1% acetaminophen vs. untreated
control. D. Survival of Abeta Tg is unchanged with 0.1% acetaminophen
vs. vehicle.
doi:10.1371/journal.pone.0027762.g004
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CCK-8 assay and dose-response curves. Following the screen in
primary cortical neurons all drugs used in the C. elegans screens
(caffeine, ciclopirox olamine, tannic acid, acetaminophen, baica-
lein, and bacitracin) were obtained from Sigma. Drug treatment
for C. elegans entailed adding 400 ul of a solution containing either
0.01%, 0.1%, or 1% (by weight) of the designated drug, dissolved
in 50% ethanol in water, to 10ml of solidified agar in a 6 cm petri
dish. Controls agar plates were treated with 50% ethanol in water
(vehicle). All drugs were added after overnight incubation at 37uC
with bacterial strains: OP50, L4440 with RNAi cassette of the
gene of interest, or L4440 (empty RNAi vector).
Phenotypic assessment
Worms were scored every other day starting at day 3 of
adulthood. Survival was assayed by prodding worms with a
platinum wire and observing movement. Lack of movement was
scored as death, following which the worm would be removed
from the plate. Scoring continued until all worms were deceased.
All studies were carried out with the experimenter blind to the
conditions (drugs and RNAi constructs) being tested. Further-
more, all results were corroborated by at least 3 separate lifespan
curves. Several drugs not reported here significantly increased
lifespan in one or more studies but the drugs reported here
significantly increased lifespan in at least 3 separate lifespan
studies.
In the CL2006 model for proteotoxicity associated with
Alzheimer’s disease [12], worms were scored daily for paralysis
starting at day 1 adult through to day 12–13 at which point all or
most of the worms had died from b-amyloid induced toxicity.
Since comparison between moribund and paralyzed becomes
unreliable as the mortality rate increases, we stopped scoring
once mortality exceeded 50%. In the initial screens worms were
scored as paralyzed if they failed to respond to prodding in the
posterior portion of the body but still moved the head and or
pharynx and dead if no movement was observed. Since both
paralysis and shortened lifespan are due to A-beta toxicity,
subsequent screens simply treated paralyzed and dead animals
the same. Nevertheless, scoring was stopped after , 50% survival
to maintain consistency. All scoring was performed blind to the
drugs being tested.
RNAi
In these studies either daf-16 or cbp-1 was inhibited using RNAi
by feeding C. elegans bacteria containing dsRNA constructs
complementary for the targeted genes [34]. The bacteria
expressing these double-stranded RNAi constructs were from
Source Bioscience.
Statistics
Statistical significance of effects on lifespan was determined
using the Kaplan-Meier test of survivorship along with the log-
rank Mantel-Cox test for median lifespan, as implemented in
Prism 4. Statistical significance of effects on age-dependent
Figure 5. Bacitracin increases N2 longevity in a CBP-1
dependent but DAF-16 independent, manner and reduces
Abeta toxicity. A. N2 longevity is increased with 01% bacitracin vs.
vehicle (P,0.01). B. Survival of daf-16 (RNAi) is increased with 01%
bacitracin vs. vehicle (P=0.01). C. Survival of cbp-1 (RNAi) is unchanged
with 01% bacitracin vs. untreated control. D. Survival of Abeta Tg is
increased with 01% bacitracin vs. vehicle (P,0.02).
doi:10.1371/journal.pone.0027762.g005
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was determined using a maximum-likelihood method implement-
ed in R, which we have extensively validated [9,18,35]. Of
particular relevance, we validated this method by demonstrating
that it predicts maximal lifespan, 50% survival time, variance in
control groups and distribution of deaths better than standard the
standard log-linear regression analysis, although the actual values
of A and G are very similar when computed by either method
[18]. Because of the increased power of this algorithm, it is possible
to estimate age-associated acceleration of mortality rate (G) and
initial mortality rate (A) using survival curves with substantially
fewer individuals than was previously required [18]. One reason
the MLE provides substantially more power than log-linear
regression is that the latter is unduly influenced by mortality rates
at the extremes of lifespan, especially toward maximum lifespan
[18]. Similarly, mean lifespan is much more sensitive than median
lifespan to the extremes of lifespan, so most standard survival curve
statistics, including the log-rank Mantel-Cox, are based on the
median rather than mean lifespan. Nevertheless, since many
studies report mean lifespan, we include these estimates for the
proposed studies as well.
Supporting information
Multiple drug screens were performed to determine the both
the efficacy and optimal concentration of drugs recovered from
the FDA approved drug library. Primary screens in C. elegans
elucidated 6 drugs capable of protecting against amyloid
induced toxicity, enhancing lifespan, or both (figure S1).
Significant increases in lifespan are observed with caffeine,
CPX, tannic acid, acetaminophen, and bacitracin (p = or , .05
as measured by Mantel-Cox). Baicalein did not yield significant
differences in this experimen t .H o w e v e r ,t r e a t m e n tw i t h
baicalein trends towards an increase in lifespan. Further, the
small sample size (n=15) likely obscures a more significant
increase, as these increases in lifespan are observed in several
other studies (data not shown).
Supporting Information
Figure S1 Survival curves of seven FDA approved drugs
discovered to be protective in a C. elegans screen.
Lifespan extension observed with caffeine A. Lifespan extension
observed with Ciclopirox olamine (B). Lifespan extension
produced by tannic acid (C). Lifespan extension produced by
acetaminophen (D). Lifespan extension observed with bacitracin
(E). Lifespan extension observed with baicalein (F).
(TIF)
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Figure 6. Baicalein increases N2 longevity in a CBP-1 depen-
dent but DAF-16 independent, manner but fails to rescue
Abeta toxicity. A. N2 longevity is increased with 0.1% baicalein vs.
vehicle (P,0.01). B. Survival of daf-16 (RNAi) is increased with 0.1%
baicalein vs. vehicle (P=0.01). C. Survival of cbp-1 (RNAi) is reduced with
0.1% baicalein vs. untreated control (P,0.01). D. Survival of Abeta Tg is
unchanged with 0.1% baicalein vs. vehicle.
doi:10.1371/journal.pone.0027762.g006
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